Hua Medicine Overview
- Year Founded
-
2011
- Status
-
Public
- Employees
-
424
- Stock Symbol
-
02552
- Investments
-
1
- Share Price
-
$0.26
- (As of Friday Closing)
Hua Medicine General Information
Description
Hua Medicine is an investment holding company. It is engaged in the development and commercialization of a first-in-class oral drug, Dorzagliatin (HMS5552), for the treatment of Type 2 diabetes. Dorzagliatin is a first-in-class glucokinase activator, or GKA, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in Type 2 diabetes. The group majorly operates and generates the majority of its revenue from the PRC.
Contact Information
Website
www.huamedicine.comCorporate Office
- Number 275 Ai Di Sheng Road
- Zhangjiang Hi-Tech Park
- Pudong, Shanghai 201203
- China
Corporate Office
- Number 275 Ai Di Sheng Road
- Zhangjiang Hi-Tech Park
- Pudong, Shanghai 201203
- China
Hua Medicine Stock Performance
As of 20-Nov-2026, Hua Medicine’s stock price is $0.26. Its current market cap is $257M with 999M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.26 | $0.26 | $0.25 - $0.50 | $257M | 999M | 1.13M | -$0.02 |
Hua Medicine Financials Summary
As of 30-Jun-2026, Hua Medicine has a trailing 12-month revenue of $93.5M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 157,295 | 282,407 | 34,402 | 154,951 |
| Revenue | 93,522 | 68,546 | 35,662 | 10,828 |
| EBITDA | (11,338) | 157,896 | (30,714) | (25,951) |
| Net Income | (15,404) | 153,846 | (34,861) | (29,857) |
| Total Assets | 222,990 | 210,061 | 209,215 | 243,401 |
| Total Debt | 52,141 | 43,116 | 41,120 | 23,665 |
Hua Medicine Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Hua Medicine Comparisons
Industry
Financing
Details
Hua Medicine Competitors (47)
One of Hua Medicine’s 47 competitors is Diamyd Medical, a Corporation company based in Stockholm, Sweden.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Diamyd Medical | Corporation | Stockholm, Sweden | ||||
| Agios Pharmaceuticals | Formerly VC-backed | Cambridge, MA | ||||
| Voyager Therapeutics | Formerly VC-backed | Lexington, MA | ||||
| Astellas Pharma | Corporation | Tokyo, Japan | ||||
| Neuphoria Therapeutics | Corporate Backed or Acquired | Millis, MA |
Hua Medicine Patents
Hua Medicine Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024284286-A1 | Glucokinase activator for cognitive disorders and neurodegenerative diseases | Pending | 06-Jun-2023 | ||
| EP-4725482-A1 | Glucokinase activator for cognitive disorders and neurodegenerative diseases | Pending | 06-Jun-2023 | ||
| US-20260248766-A1 | Glucokinase activator for cognitive disorders and neurodegenerative diseases | Pending | 06-Jun-2023 | ||
| WO-2024251159-A1 | Glucokinase activator for cognitive disorders and neurodegenerative diseases | Inactive | 06-Jun-2023 | ||
| JP-2026519840-A | Glucokinase activators for cognitive impairment and neurodegenerative diseases | Pending | 06-Jun-2023 | A61K31/4155 |
Hua Medicine Signals
Hua Medicine Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Hua Medicine Acquisitions (1)
Hua Medicine’s most recent deal was a Merger/Acquisition with Nanjing Shengderui Pharmaceutical for . The deal was made on 02-Dec-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Nanjing Shengderui Pharmaceutical | 02-Dec-2022 | Merger/Acquisition | Drug Discovery |
Hua Medicine ESG
Risk Overview
Risk Rating
Updated April, 30, 2023
34.76 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 16,421
Rank
Percentile
Pharmaceuticals
Industry
of 928
Rank
Percentile
Pharmaceuticals
Subindustry
of 456
Rank
Percentile
Hua Medicine Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Nanjing Shengderui Pharmaceutical | Nanjing, China | 2018 |
Hua Medicine FAQs
-
When was Hua Medicine founded?
Hua Medicine was founded in 2011.
-
Where is Hua Medicine headquartered?
Hua Medicine is headquartered in Pudong, China.
-
What is the size of Hua Medicine?
Hua Medicine has 424 total employees.
-
What industry is Hua Medicine in?
Hua Medicine’s primary industry is Drug Discovery.
-
Is Hua Medicine a private or public company?
Hua Medicine is a Public company.
-
What is Hua Medicine’s stock symbol?
The ticker symbol for Hua Medicine is 02552.
-
What is the current stock price of Hua Medicine?
As of 20-Nov-2026 the stock price of Hua Medicine is $0.26.
-
What is the current market cap of Hua Medicine?
The current market capitalization of Hua Medicine is $257M.
-
What is Hua Medicine’s current revenue?
The trailing twelve month revenue for Hua Medicine is $93.5M.
-
Who are Hua Medicine’s competitors?
Diamyd Medical, Agios Pharmaceuticals, Voyager Therapeutics, Astellas Pharma, and Neuphoria Therapeutics are some of the 47 competitors of Hua Medicine.
-
What is Hua Medicine’s annual earnings per share (EPS)?
Hua Medicine’s EPS for 12 months was -$0.02.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process